Here is a video with reviewer tips that I made for WI. If you often have to review documents in tracked changes, this 1-min video will help you navigate between Word’s editing views and provide you a shortcut that I use frequently.
Pharmaceutical professionals keep one foot in science and another foot in health authority regulation, both rapidly evolving fields that require consistent training to keep pace. In addition, new opportunities often entice scientists to widen their expertise to contribute to new areas of drug development, which may require an entirely new set of skills. At some point, you are likely to reach the limit of what your corporate or personal budget for training allows. This list is just what you are looking for: quality training that is either free or subsidized!
These courses are ones I have taken and felt were worth the time investment. This list is current as of February 2022.
This course (IPPCR) is offered by the NIH to train new clinical investigators from September to July of each year. It covers all aspects of clinical trials including design, analysis, reporting, budgeting, regulations, and ethics. The textbook is available for about $88 (with the promo code they provide) and the course is free, self-paced, and entirely online. If you pass the final exam you will earn a certificate of completion. This course is a significant time commitment, there are about 40 lectures and most are 60-90 minutes, and you will need to allow additional time to read the assignments and study for the exam. I highly recommend going through Statistics on Khan Academy (see below) to prepare for the biostatistics in this course.
This 6-week course offered by the Office of Regulatory Affairs and Quality (ORAQ) at Duke University is free and available online via WebEx. This course is not self-paced, there are 1-hour webcasts from 12-1 pm EST on Fridays. They take attendance and there is reading and homework.
ORAQ also offers free seminars on regulatory topics that you can join via WebEx.
This online course consists of 6 self-paced modules, which took me about 6 weeks (they estimate 8 weeks). It’s a great overview of the drug approval process and the history of the FDA. It’s presented by the Program on Regulation, Therapeutics, and Law at Harvard and Brigham and Women’s Hospital. It is free to audit, or $199 to get a certificate. It is self-paced, so you start anytime enrollment is open.
The FDA offers free online resources, including the online courses below.
If you are completely new to medical writing, this course will provide a complete overview of the field. It’s available online through ed2go and also through a partnership with community colleges (I took it through Wake Community College for less than ed2go charges).
When writing up adverse events, you need to learn a whole other language. If you are new to terms like pyrexia, dyspnoea, and tachycardia, take this brief online self-paced course on the Latin and Greek behind medical terminology. It takes about 2 hours, and is free if you don’t require a certificate.
Government communications are required to be written in plain language, but some writers are unclear what plain language means. This free online self-paced course from the National Institutes of Health (NIH) will help you understand federal requirements for plain language.
Membership to AMWA will cost you $199/year ($80 for students) but offers a lot of educational perks for medical, scientific, or regulatory writers. AMWA offers a variety of paid courses, but there are some that are free for members (search for “complimentary“), and they email out a monthly free webinar (one that is usually paid) for members as well. You also get an included subscription to the AMWA Journal and all back issues online. Membership in AMWA also includes free chapter events that are a great bargain if you live near an active chapter (if you live in NC or SC, check out @AMWACarolinas on Twitter!).
Membership in the North Carolina Regulatory Affairs Forum is only $40 and includes 6 seminars per year on regulatory topics that are available by WebEx. They also offer a summer workshop (at an additional very reasonable fee) to prepare for the Regulatory Affairs Certification (RAC) exam.
This podcast is provided by Emma Hitt Nichols of Nascent Medical to promote her business and her 6-week course. She has many interviews with medical writers, through listening you can learn about the many career paths available to medical writers as well as many tricks of the trade.
This podcast, sponsored by PSI, is excellent for statisticians and those who work with statisticians, and some episodes on leadership and influence are applicable to anyone in pharma.
Take a whirlwind tour of the past, present, and future of cancer in episode #62 of Peter Attia’s podcast. I’ve listened to this one a few times because so much interesting detail is packed into every minute of this episode.
This free magazine will keep you up to date on news, regulatory updates, and best practices for Chemistry, Manufacturing, and Controls (CMC).
This is a great monthly email newsletter for medical writers full of tips, tricks, and tools.
The European Medical Writer’s Association journal published an entire issue devoted to regulatory writing in 2014, and it’s free for non-members to read.
WI posts videos, infographics, and handouts on regulatory and medical writing topics.
Trilogy has several publications written by expert medical writers on a variety of topics.
Emma Hitt Nichols’ book on Freelance Medical Writing
Emma broadcasts a free webinar regularly to promote her 6-week course. The course is not free, but when I attended her webinar she provided her book for free to attendees.
Know of a great cheap or free course that I should list here? Contact me through the contact link above and let me know! Happy learning!
Scientists are well versed in experimental bias, which is why we address it by using experimental controls, masking our clinical trials, and using the scientific method to approach questions. However, how do we control for bias within our own minds? Cognitive bias refers to any number of ways that our brain prevents us from making entirely objective decisions. In an article that Harvard Business Review published in June 2011, “Before You Make That Big Decision…”, several types of cognitive bias are defined and discussed along with case studies, and a 12-step checklist to root out bias is defined.
Major decisions in pharmaceuticals are impacted by cognitive bias. When developing a product, there are a million decisions that can have a significant impact on the cost, timescale, clinical success, and eventual marketability of your product. Many of these decisions are originally made at the bench level, and may not be able to be changed without considerable additional time or expense as the project progresses through later stages of development.
For example, a formulator may demonstrate a bias for a particular type of formulation process because of previous experience and comfort, or the wish for high visibility through the use of trendy new technology, or convenience according to what equipment is on site and available. Decision makers should recognize the potential for this bias and make sure the best formulation is chosen regardless of the above factors. Once this formulation makes it into human studies, there is considerable inertia that makes change difficult, since the project team doesn’t want to delay timelines by having to repeat animal studies or bridge with additional human pharmacokinetic studies.
Bias can be very costly to big pharma companies, but attempts to avoid bias are not without cost. Multiple layers of peer review, involving Marketing early in development where most compounds fail for other reasons, and execution of checklists also take time, but could save billions for that one “blockbuster in the rough.”
According to the article, it is nearly impossible to detect your own bias, but through learning about bias, we can better detect it in our peers and use this knowledge to better challenge decisions. For example, when performing due diligence, you must be alert for bias from the company under scrutiny, the fellow members of your team, and in how your team prioritizes and reports the findings.
Here are some types of bias from the article and how they could come up in pharma:
This type of bias is hard to avoid. Almost every person on a project team is heavily vested in the success of their project. Part of this is due to corporate culture, which tends to reward those people who happen to be on successful projects. This bias can be minimized by shifting the focus from project success, which can be largely due to the luck of being assigned to a safe and effective compound, to excellence in contributing to the project. Another similar bias is loss aversion, a fancy business term for “fear of failure.” Pharma is understandably already risk-averse, but it is also disadvantageous to have people avoiding difficult projects, or killing projects that are a deviation from the norm without sufficient basis. If people on failing projects are rewarded for swiftly contributing to clinical evaluation and cost-effectively killing their project, there is less motivation to “succeed at all costs” or “run for the hills.”
In a similar vein, even when project members’ fates are not tied to a project outcome, a project team can fall in love with a concept after expending a lot of hard effort, which also makes an objective analysis of the product’s value difficult. In this case, it is up to the peer reviewers or due diligence team to make sure that they are getting a clear picture and not an overly positive projection based on the best subset of data.
Groupthink is the result of insufficient diversity on the team or strong dominant members that quash all dissent before it can be fully explored. If you have a group of scientists from similar backgrounds, who have been working together in the same field for a long time, groupthink can occur. Most Big Pharma companies indirectly solve groupthink by aggressively promoting diversity and reorganizing fairly often, so you aren’t working with the same people for more than a few years. Groupthink can be challenged head-on in peer review by considering the people making up the team- was there enough varied expertise? Were all voices heard?
There is a whole book devoted to this type of bias. Where does it come up for pharma? In audits of suppliers and due diligence for in-sourcing, this bias can be difficult to avoid. A related bias is the saliency bias, where a previous success casts a rosy glow on a new, similar project. The halo effect can come up in decisions regarding outsourcing. If you have a company that you love and frequently use for analytical capability, that positive association may bias you to choose them for formulation work, even though it may turn out that their capabilities for formulation are insufficient. As common as this bias is, at least it is easier to spot than some other types of bias. Auditing and due-diligence teams will benefit from reminding themselves of this potential bias before visiting a favorite supplier, as tempting as a shortened visit would be.
This bias may be the most insidious for pharma. In confirmation bias, the team generates one path forward and seeks only data to support the chosen path, disregarding all else. In drug development, each decision builds over a thousand smaller previous decisions. A common pitfall in oral formulation development is dose. Early in development, a high dose is required, so you develop a melt granulation. Later in development, when the dose has dropped to 10 mg, did the project team scale down the melt granulation, or evaluate a cheaper dry blend process?
There is much scientific information to evaluate in the early stages of product development. Even still, many times you have to move forward with less info than you would like. Analytical testing is a bit like exploring a cave with a flashlight, where the light cast by the flashlight is the capability of your test. Is there anything lurking in the shadows? It’s important to do a risk assessment based on what data is missing at the time of the decision and evaluate “what ifs.” What if the drug substance supply was not an issue? What if you had another month to develop? How would the decision change? Should a contingency plan be in place in case a critical factor does change?
For example, many times your first formulation is developed while your salt program is ongoing. For now, you are assuming your compound is insoluble, but what if a soluble salt is found? How will this change your approach? Do you have a workable backup plan?
Sunk Cost Fallacy
Pharma is very susceptible to the sunk cost fallacy because it is just so expensive to develop a drug. The sunk cost fallacy is when you, for better or worse, factor in past cost/resource into a decision for the future.
Consider the simplistic hypothetical case where you have a drug that you have already spent $500 million developing. The Food and Drug Administration (FDA) then restricts your patient population, driving the market forecast from blockbuster level to only $5 million a year over a projected remaining patent life of 7 years. You have $5 million in expected future costs prior to launch. If you consider the sunk costs, this project is a loser, and you may be tempted to cut your losses and save $5 million. However, if you ignore the past money spent and focus only on the future, the return on investment is pretty good.
The sunk cost fallacy can also work in the opposite way and be a powerful companion to the self-interest bias and related biases above, also known as the “We Have to Make This Work Because We Have Already Spent Ungodly Sums on It” bias.
Considering the impact and cost of bias to Big Pharma, an organizational assessment to determine how susceptible you are to bias may be in order:
– How aware are your project teams of cognitive bias and how to recognize it? Is this awareness only at the executive level, or does it reach to your bench-level decision makers?
– How are your decisions controlled? Is there peer review? Are the peer groups involved sufficiently diverse?
– Is your corporate or departmental culture breeding bias? Are people rewarded based on only project success? Have you ever rewarded a “positive failure”? Are dissenting opinions welcomed?
– Are there physical or process factors that could create bias in your decisions? For example, scientists may have a bias toward equipment housed in the same building as their office. If ordering a new excipient requires multiple forms and a six-month auditing process, there will be a strong preference for what’s already in the warehouse.
Pharmaceutical employees weather a perfect storm of conditions that promote bias: high financial stakes, a strong scientific drive to produce successful results, considerable time pressure, and a highly regulated environment resistant to change. A pharma company that promotes awareness of bias and implements effective counter-measures at all levels of the organization can sail through this storm toward better outcomes.
- Kahneman D, Lovallo D, Sibony O. The Big Idea: Before You Make That Big Decision… https://hbr.org/2011/06/the-big-idea-before-you-make-that-big-decision. Accessed January 19, 2019.
- Rosenzweig, Phil. The Halo Effect: . . . and the Eight Other Business Delusions That Deceive Managers. Free Press, 2014.
Thanks for visiting. I’ve been writing a blog since 2011, prior to my career shift to medical writing. The previous blog posts can be viewed on Blogger, and are informal and fun posts on a variety of pharmaceutical topics and give a hint to my personality. As I polish up those posts to a more professional style or create new ones, they will be posted here.
Here’s a shortcut to my most most popular post: Free and Low-cost Training for Medical Writers and Pharma Scientists.
The heart and soul of good writing is research; you should write not what you know but what you can find out about.
— Robert J. Sawyer